Tourangeau Greg 4
4 · Fulcrum Therapeutics, Inc. · Filed Jan 30, 2024
Insider Transaction Report
Form 4
Tourangeau Greg
Principal Accounting Officer
Transactions
- Award
Stock Option (right to buy)
2024-01-26+83,820→ 83,820 totalExercise: $6.95Exp: 2034-01-25→ Common Stock (83,820 underlying) - Award
Stock Option (right to buy)
2024-01-26+10,000→ 10,000 totalExercise: $6.95Exp: 2034-01-25→ Common Stock (10,000 underlying)
Footnotes (2)
- [F1]This option was granted on January 26, 2024 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2024, subject to the reporting person's continued service on each such vesting date.
- [F2]This option was granted on January 26, 2024 and is scheduled to vest in equal yearly installments over two years beginning on the vesting commencement date of January 1, 2024, subject to the reporting person's continued service on each such vesting date.